sales@kintaibio.com    +86-133-4743-6038
Cont

Have any Questions?

+86-133-4743-6038

Apr 18, 2025

KintaiBio Nature’s Power:Aconitum Extract As A Next-Gen API

kintaibio® Harnesses the Power of Nature: Himalayan Aconitum Extract Emerges as a Next-Generation Plant-Derived API

As the global pharmaceutical industry increasingly turns to naturally sourced active pharmaceutical ingredients (APIs), kintaibio® is leading the way with its innovative product, Lappaconitine Hydrobromide. Derived from the rare Himalayan plant Aconitum heterophyllum, this alkaloid demonstrates the promise of "green pharmaceuticals," offering safer and more sustainable solutions for pain relief and anti-inflammatory treatments.

 

Botanical Renaissance: The Rise of Natural API
Regulatory agencies like the FDA and EMA are fast-tracking approvals for plant-derived APIs like paclitaxel and artemisinin, driving the market for natural medicines to grow at an annual rate of 8.5% (Grand View Research). kintaibio® capitalizes on this trend, specializing in high-value botanical extracts. Their flagship product, Lappaconitine Hydrobromide, has achieved ICH-GMP certification and offering a greener alternative to synthetic APIs..

 

The Story Behind Aconitum heterophyllum
Aconitum heterophyllum, growing at altitudes over 3,000 meters in the Himalayas, has been used for centuries in Tibetan and Ayurvedic medicine for pain relief and fever reduction. By utilizing patented supercritical CO₂ extraction technology, kintaibio® isolates Lappaconitine Hydrobromide from the plant's roots with over 99.8% purity-well above international standards. Key benefits of this extract include:

 

  • Non-Addictive Pain Relief: Works by blocking pain signals without the addiction risks associated with opioids.
  • Anti-Inflammatory & Immune Benefits: Clinical trials show positive results in rheumatoid arthritis models (J. Ethnopharmacol., 2022).
  • Lower Toxicity: The hydrobromide form reduces cardiac toxicity compared to traditional aconitine alkaloids.
  • Sustainable Supply Chain: Green Farming and Eco-Friendly Production

 

To address the scarcity of wild Aconitum heterophyllum, kintaibio® has established 2,000 acres of eco-farming sites in Tibet and Nepal, using wild-simulated cultivation techniques that ensure traceability and biodiversity conservation. Their facilities are powered by solar energy and use zero-wastewater recycling systems, cutting their carbon footprint by 40%-in line with the EU's Green Deal environmental standards.

 

Global Expansion: Partnering for the Future of Natural APIs
kintaibio® has formed strategic partnerships with major global pharmaceutical companies to develop extended-release tablets and transdermal patches based on Lappaconitine Hydrobromide. CEO Chen Jinfeng stated, "We're investing $5 million in a new smart extraction facility to increase annual production capacity to 10 metric tons by 2025, meeting 20% of global demand for plant-based pain relief APIs."

 

About kintaibio®
kintaibio® is a leading supplier of natural APIs in Asia, specializing in high-purity bioactive compounds derived from rare medicinal plants. With certifications such as ISO 22000 and FDA DMF filings, the company offers end-to-end green solutions, from seed to medicine, with applications in oncology, neuroprotection, and anti-infectives.

 

Plant-Derived APIs Gaining Momentum

  • Cepharanthine: Extracted from Stephania cephalantha, this compound shows promise in treating COVID-19 by inhibiting viral entry and modulating calcium channels (Clinical trials by PharmaDrug).
  • Artemisinin: A key antimalarial from Artemisia annua, now being explored for its potential to combat SARS-CoV-2 (Scientific Reports).
  • Tripterin: Derived from Tripterygium wilfordii, this liposomal formulation shows promise in treating severe pneumonia and ARDS in preclinical trials (Signal Transduction and Targeted Therapy).
  • Ginkgo Biloba Extract: Standardized extracts like EGb 761 have been proven to improve cognitive function, supported by global clinical trials.
  • These innovations highlight the growing role of plant-based APIs in treating both chronic and emerging diseases.

Looking ahead, the company will continue to focus on plant-based APIs products, driving the global expansion of Chinese ingredients into the high-end value chain. For more product details, please contact: Our Website is kintai-bio.com | sales@kintaibio®.com

Send Inquiry